Cystic Fibrosis Lung Function Improved With Triple Therapy
Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and...
Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently...
#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Pha
Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency...
FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI
AzurRx BioPharma is planning a multi-center Phase 2 trial to be conducted in the United States and Europe to evaluate its lead candidate...
Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways
New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...
Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment
Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum...
MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial
AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential...
Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity
Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational...
New Approach Against Antibiotic-resistant Bacteria in CF Patients Shows Promise in Phase 1 Trial
Researchers may have found a new way of treating antibiotic-resistant bacterial infections, specifically Pseudomonas aeruginosa, in the...
